The DOI matches its Crossref record; 427 of the 428 references it cites were found in a registry or an index; 82 of the 464 sources its claims cite were checked for support.
TGFβ biology in cancer progression and immunotherapy
Open accessAbstract
TGFβ signalling has key roles in cancer progression: most carcinoma cells have inactivated their epithelial antiproliferative response and benefit from increased TGFβ expression and autocrine TGFβ signalling through effects on gene expression, release of immunosuppressive cytokines and epithelial plasticity. As a result, TGFβ enables cancer cell invasion and dissemination, stem cell properties and therapeutic resistance. TGFβ released by cancer cells, stromal fibroblasts and other cells in the tumour microenvironment further promotes cancer progression by shaping the architecture of the tumour and by suppressing the antitumour activities of immune cells, thus generating an immunosuppressive environment that prevents or attenuates the efficacy of anticancer immunotherapies. The repression of TGFβ signalling is therefore considered a prerequisite and major avenue to enhance the efficacy of current and forthcoming immunotherapies, including in tumours comprising cancer cells that are not TGFβ responsive. Herein, we introduce the mechanisms underlying TGFβ signalling in tumours and their microenvironment and discuss approaches to inhibit these signalling mechanisms as well as the use of these approaches in cancer immunotherapies and their potential adverse effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
35 Valid · 6 Not valid · 182 Not checked · 57 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Cells have a remarkable ability to rapidly upregulate TGF-β responsiveness by inducing receptor transport to the cell surface, thus enhancing the availability of receptors for TGF-β binding91,92.”
§ TGF-β biology in cancer progression and tumor immunotherapy > Fundamentals of TGF-β biology with relevance to cancer
What the sources say
- Not checked yetcites [91] Budi, E. H., Muthusamy, B. P. & Derynck, R. The insulin response integrates increased TGF-β signaling through Akt-induced enhancement of cell surface delivery of TGF-β receptors. Sci. Signal. 8, ra96 (2015).
- Supportedcites [92] Wu, L. & Derynck, R. Essential role of TGF-β signaling in glucose-induced cell hypertrophy. Dev. Cell 17, 35–48 (2009). source
The Results section (“Glucose increases the cell surface expression of TGF-β receptors”) reports a rapid increase in surface receptors and concludes that glucose stimulates their transport from intracellular compartments. The Discussion section (“Glucose rapidly and selectively enhances the cell surface presentation of TGF-β receptors”) says this increases ligand-binding capacity and sensitivity to TGF-β. Page numbers are not provided in our copy. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although divergent observations are reported156,157, TGF-β treatment and EMT-associated CSC properties correlate with a decreased ability of carcinoma cells to repair double-stranded DNA breaks and increased genomic instability158,159.”
§ TGF-β biology in cancer progression and tumor immunotherapy > TGF-β promotes differentiation plasticity, stem cell properties and cancer drug resistance.
What the sources say
- Partly supportedcites [158] Comaills, V. et al. Genomic instability is induced by persistent proliferation of cells undergoing epithelial-to-mesenchymal transition. Cell Rep. 17, 2632–2647 (2016). sourceExperimental — accuracy not yet measured
The Results section, “EMT promotes genomic instability and tumorigenicity” (page unavailable), reports heritable chromosomal abnormalities after TGF-β exposure. The Discussion (page unavailable) also reports increased DNA damage and genomic instability in cells undergoing EMT. These passages do not establish decreased double-strand-break repair ability or link that ability to EMT-associated cancer stem-cell properties. (LLM, conf=0.86)
- Not checked yetcites [159] Pal, D. et al. TGF-β reduces DNA ds-break repair mechanisms to heighten genetic diversity and adaptability of CD44+/CD24- cancer cells. elife 6, e21615 (2017).
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Of further therapeutic relevance, EMT enables carcinoma cells to exert local immunosuppression143,144. EMT confers repression of major histocompatibility complex class I (MHCI) antigen presentation by tumor cells, which is required for recognition by CD8+ T cells, and thus indirectly suppresses cytotoxic activities of CD8+ T cells and cytolytic activities of NK cells141,143–145.”
§ TGF-β biology in cancer progression and tumor immunotherapy > TGF-β promotes differentiation plasticity, stem cell properties and cancer drug resistance.
What the sources say
- Partly supportedcites [141] Dongre, A. et al. Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Res. 77, 3982–3989 (2017). sourceExperimental — accuracy not yet measured
The Results (page unavailable) show that EMT reduced tumor-cell surface MHC-I and β2-microglobulin, while mesenchymal tumors had fewer CD8+ T cells with signs of exhaustion. The Discussion (page unavailable) says MHC-I-low tumors were not eliminated despite greater NK-cell infiltration, attributing this to other immunosuppressive cells such as Tregs. The paper does not establish repression of the broader antigen-processing machinery or show that reduced MHC-I itself suppresses NK cytotoxicity. (LLM, conf=0.86)
- Partly supportedcites [143] Soundararajan, R. et al. Targeting the interplay between epithelial-to-mesenchymal-transition and the immune system for effective immunotherapy. Cancers 11, 714 (2019). sourceExperimental — accuracy not yet measured
Sections 3 and 6 link EMT to cancer-cell-mediated immunosuppression, and section 5 says EMT-associated checkpoint molecules inhibit T-cell cytotoxicity. The paper discusses MHC downregulation and loss of antigen processing as possible tumor escape mechanisms in section 4, but does not say EMT causes them. Section 5 also says EMT may increase, rather than suppress, sensitivity to NK-cell cytotoxicity. Page numbers are unavailable in our copy. (LLM, conf=0.85)
- Partly supportedcites [144] Terry, S. et al. New insights into the role of EMT in tumor immune escape. Mol. Oncol. 11, 824–846 (2017). sourceExperimental — accuracy not yet measured
The sections on CTL resistance and immunological synapses report antigen-presentation defects in mesenchymal carcinoma cells and reduced MHC class I expression associated with impaired CTL interactions. The paper also reports resistance to NK-cell lysis, but attributes it at least partly to defective immune-synapse signaling—not to reduced MHC class I. Its section on NK-cell resistance says reduced MHC class I can instead make cancer cells susceptible to NK cells, though that reduction is rarely sufficient to trigger lysis. (LLM, conf=0.88)
- Partly supportedcites [145] Dodagatta-Marri, E. et al. α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas. J. Immunother. Cancer 7, 62 (2019). sourceExperimental — accuracy not yet measured
The Results section, “TGFβ induces EMT and reduces expression of tumor cell antigen presentation genes in CCK168 cells” (page unavailable), reports that TGFβ induced EMT and suppressed Mhc1, B2m, Tap1 and Tap2 expression in cultured carcinoma cells. It says these changes might affect cytotoxic T-cell recognition, but does not show reduced antigen presentation or CD8+ cytotoxic activity, and does not address NK-cell cytotoxic activity. The citing sentence states those functional effects more definitively than the source supports. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“As in other immune cell types, TGF-β/Smad signaling represses interferon-γ (IFN-γ) expression that supports myeloid cell and CD8+ T cell proliferation and differentiation168.”
§ TGF-β biology in cancer progression and tumor immunotherapy > Diverse roles of TGF-β in innate immune cell populations in cancer
What the sources say
- Partly supportedcites [168] Naganuma, H. et al. Transforming growth factor-β inhibits interferon-Gamma secretion by lymphokine-activated killer cells stimulated with tumor cells. Neurol. Med. Chir. 36, 789–795 (1996). sourceExperimental — accuracy not yet measured
The Discussion reports that TGF-β inhibited IFN-γ secretion by tumor-stimulated lymphokine-activated killer cells. It does not establish that this occurs through Smad signaling or that IFN-γ supports myeloid-cell and CD8+ T-cell proliferation and differentiation. Page numbers are not available in our copy. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“EMT also confers increased cancer cell expression of PD-L1, the ligand for the immune-inhibitory PD-1 receptor on CD8+ T lymphocytes141,146.”
§ TGF-β biology in cancer progression and tumor immunotherapy > TGF-β promotes differentiation plasticity, stem cell properties and cancer drug resistance.
What the sources say
- Supportedcites [141] Dongre, A. et al. Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Res. 77, 3982–3989 (2017). source
The RESULTS passage (p. Results, 'We also observed that the more mesenchymal cell lines…') states that activation of an EMT in epithelial cell lines via doxycycline-inducible EMT-TFs 'resulted … in increased expression of PD-L1', and that tumors from mesenchymal lines contained a higher percentage of PD-L1-positive cells, attributing this to 'the cell-autonomous actions of the EMT program'; the Abstract likewise contrasts epithelial (low PD-L1) with mesenchymal/EMT-marker-positive (high PD-L1) tumors. The accompanying gloss that PD-1 is the immune-inhibitory receptor on CD8+ T lymphocytes is consistent with the same paper, which reports that the few CD8+ T cells in mesenchymal tumor stroma co-expressed PD-1 and CTLA4 (RESULTS, Fig 1B). The only scope caveat is that the demonstration was made in breast/mammary carcinoma models (human breast lines and MMTV-PyMT mouse tumors), whereas the citing sentence phrases it generically as 'cancer cell'. (LLM, conf=0.88)
- Not checked yetcites [146] Jiang, Y. & Zhan, H. Communication between EMT and PD-L1 signaling: new insights into tumor immune evasion. Cancer Lett. 468, 72–81 (2020). source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
165 more claims · 35 with their cited sources checked
Create a free account to see all 280 claims and to verify the 382 references still open.
- It may state two separate claims as one. 104
- Probably not a substantial claim. 9
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, cancer cells adapt to the protective TGF‐β signaling and utilize its moonlighting functions to create a conducive TME by activating CAFs, promoting angiogenesis and ECM production, and suppressing anti‐tumor immune responses [160, 161, 162].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [161]
In the citing paper
“TGF-β signaling can produce profound immunosuppressive activity on crucial cell types of innate and adaptive immunity, thereby attenuating the inherent anti-tumor potential of immune cells within TME [214].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [214]
In the citing paper
“TGF-β signaling activation plays a key role in cancer progression and is associated with tumor treatment resistance [214].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [214]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ TGF-β biology in cancer progression and tumor immunotherapy > Combining TGF-β blockade with immune checkpoint blockade
“Checkpoint blockade enhanced their Th1/ Treg ratio, and this was reversed and further diminished by TGF-β blockade, accounting for anti-tumor synergy between both drugs145.”
§ TGF-β biology in cancer progression and tumor immunotherapy > References
“145. Dodagatta-Marri E. α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas.”
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091
Self-citationCell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Research works printed but not linked: 1
- Reed, N. I. et al. The αvβ1 integrin plays a critical in vivo role in tissue fibrosis. Sci. Transl Med. 7, 288ra279 (2015).
Cited by
Harnessing cytokines and chemokines for cancer therapy
Propper, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 989
TGF-β signaling in health and disease
Massagué, J., & Sheppard, D. (2023) · Cell · doi:10.1016/j.cell.2023.07.036 · Cited by 890
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773
Dynamic EMT: a multi‐tool for tumor progression
Brabletz, S., Schuhwerk, H., Brabletz, T., & Stemmler, M. P. (2021) · The EMBO Journal · doi:10.15252/embj.2021108647 · Cited by 761
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 727
Metadata
- Authors
- Derynck, R., Turley, S. J., & Akhurst, R. J.
- Affiliations
- University of California, San Francisco (US)
- Genentech (US)
- Corresponding author
- Derynck, Rik
- Turley, Shannon J.
- Akhurst, Rosemary J.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2020-07-24
- Volume
- 18
- Issue
- 1
- Pages
- 9-34
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- PMC
- PMC9721352
- OpenAlex
- W3044737312
- Cited by
- 944
- References
- 428
- Citations by year
- 2026: 147 · 2025: 191 · 2024: 195 · 2023: 167 · 2022: 151 · 2021: 81 · 2020: 9
- FWCI
- 10.05
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute (R01CA210561)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- TGF-beta signaling, tumor progression, tumor microenvironment, cancer immunotherapy, immunosuppression, epithelial plasticity, cancer stemness, treatment resistance, tumor invasion, stromal fibroblasts, TGF-beta inhibition
- MeSH terms
- Animals, Humans, Immunotherapy, Neoplasms, Signal Transduction, Transforming Growth Factor beta, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TGFβ biology in cancer progression and immunotherapy. https://app.cochat.ai/papers/10.1038/s41571-020-0403-1
- The paper
- Derynck, R., Turley, S. J., & Akhurst, R. J. (2021). TGFβ biology in cancer progression and immunotherapy. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-020-0403-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.